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In real-world clinical practice, underdosing, i.e. off-label use of reduced doses (RD), of oral 
factor Xa inhibitors (oFXaIs) is quite common in stroke prevention in nonvalvular atrial 
fibrillation, possibly reflecting the hope to increase safety without reducing efficacy in selected 
patients. To assess whether this strategy is associated with some clinical benefit, we used a 
physician-centered approach to evaluate whether current evidence supports the hypothesis that 
a substantial proportion of underdosing may be voluntary rather than casual, whether and to 
what extent oFXaIs’ dose rather than patients’ characteristics are associated with bleeding 
events, and which are the safety and efficacy clinical implications of oFXaIs’ underdosing. 
Our review found consistent evidence that underdosing is often an intentional strategy; 
however, available studies do not demonstrate a sizeable net clinical benefit of using off-label 
RD oFXaIs. 
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ONE SENTENCE SUMMARY: Available evidence does not demonstrate a sizeable net 
clinical benefit of off-label use of oFXaI RDs, rather suggesting an increased risk of adverse 
events, including hospitalizations for cardiovascular causes and stroke, without a consistent 












INTRODUCTION AND SCOPE OF THE REVIEW 
Since the net clinical benefit of direct oral anticoagulants (DOACs) over warfarin has been 
demonstrated in randomized clinical trials (RCTs)1–4, DOACs have become the recommended 
first line therapy for stroke prevention in nonvalvular atrial fibrillation (NVAF). These 
medications are fixed-dose oral regimens available in two different dose options, which have 
been variously named (standard, full or higher dose, and reduced or lower dose); anyway, dose 
prescription should be in keeping with drug‐ specific dosing guidelines5–7. The criteria for 
posology adjustment and approved doses of oral factor Xa inhibitors (oFXaIs) for stroke 
prevention in NVAF according to the European Medicines Agency summary of product 
characteristics (SmPC) are available in Supplementary Data Tables S1 and S2, respectively. 
Use of reduced dose (RD) DOACs is primarily recommended along the published European 
guidelines dose reduction criteria7. 
In this regard, however, the differences in the RCTs’ design may help to clarify the question 
of appropriate or inappropriate use of DOAC doses and to uniform the terminology. In the RE-
LY trial patients were randomly assigned to receive dabigatran at a dose of 150 mg or 110 mg 
twice daily (BID), both showing consistent efficacy and safety across a wide range of NVAF 
patients, with an increasing net clinical benefit when prescribed according to European 
recommendations1,7–10. Being independent from any patient’s characteristics, the selection of 
the lower dabigatran dose is entirely at the physician's discretion, mainly based on patient’s age, 
renal function and concomitant drug therapies, and should not be regarded as inappropriate7. 
On the other hand, in RCTs investigating the non-inferiority of oFXaIs over warfarin, patients 
received full dose (FD) or reduced dose (RD) of the experimental drug according to predefined 
criteria2–4. In the ENGAGE AF-TIMI 48 study, higher dose (HDE) and lower dose (LDE) once-
daily (OD) edoxaban regimens have been evaluated, each including a RD according to pre-











been observed a 41% higher ischemic stroke risk compared with warfarin, leading to the non-
approval of this dosing regimen. Therefore, prospective RCTs data for lower doses only exist 
for dabigatran (110 mg BID) and edoxaban (30/15mg OD, but not approved)7. In contrast, no 
lower dose group was studied for rivaroxaban in the ROCKET AF trial2 and for apixaban in the 
ARISTOTLE trial3, but eligibility for the RD arm was predefined according to the patient’s 
characteristics; as such, no clinical outcome data on hard end-points are available for the use of 
these doses outside the tested dose reduction algorithms7. Therefore, the issue of inappropriate 
(or off-label) use of RD DOACs in patients not meeting the criteria for dose reduction (i.e., 
underdosing) mainly concerns oFXaIs, and is by far more common than inappropriate use of 
FD in patients who qualify for RD (i.e., overdosing)11–50. Undoubtedly, some underdosing may 
be ascribed to involuntary errors or to physiological fluctuations of creatinine clearance (CrCl) 
around the dose-reduction level, but a substantial proportion of it might reflect an intentional 
“cautious” approach to DOAC use in selected patients, implying high hopes that underdosing 
may lessen the risk of bleeding without reducing the efficacy in stroke prevention. In fact, 
some uncertainties in dose selection may arise when considering that the latest European 
recommendations for practical use of DOACs suggest to consider the use of a RD in the 
presence of two or more factors including, among others, age over 75 years, previous bleeding, 
frailty and high fall risk7. This may appear somehow counterintuitive since the risk of 
thromboembolic events has been demonstrated to further increase in very advanced age51 and 
age over 75 years is the most powerful risk factor for stroke in NVAF patients52. Moreover, 
frail older patients with NVAF are less likely to receive an appropriate oral anticoagulant 
therapy (OAT) and, at the same time, are at greater risk of embolic stroke and death53,54. It has 
been well demonstrated that patients on OAT at high risk of falls have not a significantly 
increased risk of major bleeding (MB)54, and current recommendations do not require fall risk 











with NVAF and frailty might in part explain the gap between current recommendations not to 
undertreat frail older patients55 and the high prevalence of underdosing in real-life patients53,54. 
In order to assess whether there is some evidence of a potential clinical benefit for oFXaIs’ 
underdosing, we will use a physician-centered approach to evaluate current literature for the 
presence of 1) evidence supporting the hypothesis that a substantial proportion of underdosing 
may be voluntary rather than casual; 2) a possible association of oFXaIs’ dose with bleeding 
events, and its extent; and 3) data on the safety and efficacy clinical implications of oFXaIs’ 
underdosing. We will not discuss DOAC dose adjustment strategies according to plasma 
concentration because, despite some potential benefit has been observed in small studies56–59, 
there is no evidence from large RCTs that this strategy may be associated with a higher clinical 
benefit compared with current practice7. 
 
METHODS 
The medical literature was systematically searched through Pubmed (MEDLINE) and Embase 
using a combination of Medical Subject Heading (MeSH) terms and keywords relevant for the 
treatment and conditions of interest for primary studies and systematic reviews. Search was 
limited to studies published in English language, between January 2010 and May 2020. 
Predefined exclusion criteria included: basic science and animal studies, studies focusing on 
different drug molecules (e.g., ximelagatran, anticoagulation reversal agents including 
idarucizumab), on specific non-relevant conditions (e.g., NVAF ablation, periprocedural OAT, 
end-stage chronic kidney disease – CKD - and hemodialysis), on outcomes not relevant for the 
purpose of this review (e.g. cost-effectiveness, medication adherence, quality of life), wrong 
publication types (e.g. case reports, abstracts and oral communications), and studies with 















Underdosing of oral factor Xa inhibitors in real-life clinical practice 
In real-life, patients with NVAF are older, more frequently of female gender, and show a high 
prevalence of comorbidities, polypharmacy and functional and/or cognitive impairment54, with 
a high prevalence of RD use11–50,54,60, particularly for apixaban. A descriptive summary of the 
systematically identified studies which investigated the prevalence of and the variables 
associated with off-label use of oFXaI RDs is available in Supplementary data, Table S3. In the 
ORBIT-AF II study underdosing was associated with older age, female gender, and higher 
embolic and bleeding risk scales13, as well as with non-white ethnicity61. DOAC underdosing 
in 6658 Canadian primary care patients (7.2%) was associated with female gender, presence of 
multiple comorbidities (particularly heart failure and dementia) and concomitant therapy with 
aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)17. Among 460 older outpatients, 
underdosing (18%) was associated with older age, higher embolic risk score, previous MB and 
history of CKD18. In a sample of 772 hospitalized patients, factors associated with inappropriate 
DOAC prescribing (mainly represented by underdosing, 17.4% in the overall sample) were, 
among others, age ≥80 years, apixaban prescription, and moderate CKD24. In a large sample of 
8425 newly prescribed NVAF patients, underdosing (39%) was associated at univariate 
analysis with several variables, including, among others, female gender, advanced age, lower 
BMI, history of CKD and lower CrCl, greater comorbidity burden, higher embolic risk score 
and concomitant use of antiplatelet drugs30. Among others, age over 80 years alone, history of 
bleeding or high perceived bleeding risk have been reported as reasons for persistent apixaban 











(18.1%) was more frequent with advancing age, despite normal renal function and body weight 
(BW)32. Among 30467 outpatients with NVAF from UK primary care, underdosing was 
observed in 21.6% and 9.1% of patients that initiated treatment with apixaban and rivaroxaban, 
respectively, with increasing use of RD along with lower CrCl33. Of note, 26.9% of apixaban-
underdosed patients met none dose reduction criteria33. In a recent systematic review, Santos et 
al reported data from 75 studies and showed that a substantial proportion of patients (25-50%) 
received off-label DOACs doses14. 
In conclusion, in real-life clinical practice, underdosing is quite common, particularly for 
apixaban. Several conditions, including advanced age, female gender, higher embolic and 
bleeding risk scores, history of bleeding and/or perceived high risk of bleeding, history of 
CKD, concomitant use of antiplatelet drugs or NSAIDs, have been consistently reported to be 
associated with underdosing, supporting the hypothesis that a substantial proportion of off-
label RD oFXaIs’ prescriptions may be voluntary rather than casual11,13–50,62. 
 
Oral factor Xa inhibitors’ dose, patients’ characteristics and bleeding events 
In the ROCKET AF study, patients who experienced a gastrointestinal bleeding (GIB) were 
older and less often female2. GIB occurred in the upper gastrointestinal (GI) tract (48%), lower 
GI tract (23%), and rectum (29%), without differences between treatment arms2,63. 
Rivaroxaban-treated patients with MB were more likely to be older, have a history of chronic 
obstructive pulmonary disease or GIB, prior use of aspirin, mild anemia and diastolic blood 
pressure ≥90 mmHg64. Compared with FD-treated patients, those treated with RD rivaroxaban 
(20.7%) were older, more frequently of female gender, with a greater comorbidity burden and 
higher stroke risk2,65. The primary safety endpoint (MB and clinically relevant non-major 
bleeding, CRNMB) occurred more frequently in those treated with RD rivaroxaban than in 











hemorrhagic stroke, intracranial hemorrhage and fatal bleeding were consistently higher among 
patients eligible for RD, irrespective of treatment allocation65,66. 
In the overall sample of the ARISTOTLE study, the incidence of MB, which was lower in the 
apixaban group3, increased with advancing age (75 years or older), this latter being 
independently associated with an increased risk of bleeding, along with history of hemorrhage, 
stroke or transient ischemic attack (TIA), concomitant use of antiplatelet drugs or NSAIDs, 
diabetes, lower CrCl, and anemia prior to treatment67. Patients eligible for apixaban RD were 
older and at increased risk of stroke, MB and all-cause death compared with the subjects on 
FD66,67. However, the effect of properly used RD apixaban versus warfarin in these patients 
was consistent with that of the FD in reducing stroke, MB and all-cause mortality68,69. Patients 
with only one dose reduction criterion and appropriately treated with FD apixaban did not show 
differences in the efficacy and safety outcomes compared with FD-treated patients who did not 
fulfill any dose reduction criteria70. In patients with prior GIB (who were at increased risk of 
recurrent major GIB) treated with an appropriate apixaban dose, efficacy and safety were 
consistent with the results of the overall trial71. The use of NSAIDs was associated with incident 
MB e CRNMB, but not with GIB72. 
In the AVERROES trial, the rate of bleeding events was 3.8%/year and 4.5%/year with aspirin 
and apixaban, respectively73. The anatomic site of bleeding did not differ between therapies, 
and higher embolic risk scores were associated with increasing risk of both bleeding and 
stroke73. Rates of MB on apixaban were similar to those of aspirin across all age groups, and 
increased with age, with absolute rates of 2.6%/year and 2.2%/year, respectively, in patients 75 
years and older, compared with 0.8%/year and 0.7%/year, respectively, in patients under 75 
years, with no significant treatment-by-age interaction74. Moreover, the risk of MB in patients 











In the ENGAGE AF-TIMI 48 trial, the annualized rate of MB was significantly reduced in 
patients treated with HDE (2.75%) and with LDE (1.61%) compared with warfarin (3.43%), 
whereas the risk of major GIB was higher with HDE, but lower with LDE4. In the overall sample 
of patients, several variables were associated with an increased risk of major GIB, including 
older age, male gender, comorbidities (particularly heart failure, diabetes and CKD), and 
concomitant use of aspirin or other antiplatelet agents, and of proton pump inhibitors (PPIs) or 
other gastro-protective agents75. Patients who met criteria for dose reduction at randomization 
had a higher risk of stroke, bleeding and death compared with those who did not fulfill dose-
reduction criteria66,76. 
These data from RCTs demonstrate that several patients’ characteristics (including older age, 
greater comorbidity burden, CKD, previous bleeding events, use of NSAIDs and antiplatelet 
drugs), rather than oFXaIs’ dose, are significantly and consistently associated with an increased 
occurrence of MB in oFXaI-treated patients. Rates of MB were consistently higher among RD-
treated than in FD-treated patients66. However, appropriately dose-adjusted oFXaIs showed an 
improved benefit-harm profile compared with warfarin and with aspirin66,73. Of note, in elderly 
patients rates of MB were similar on apixaban and on aspirin in the unique study comparing a 
DOAC with aspirin74. 
Real-life studies demonstrated that in OAT-treated patients most MBs occur in subjects with 
underlying gastrointestinal (GI) pathology (colonic diverticula, angiodysplasia, peptic ulcer 
disease, arteriovenous malformations, inflammatory bowel disease, hemorrhoids and 
malignancy77,78. Older age is associated with an increased prevalence of these underlying 
conditions, predisposing to bleeding, and this risk is further increased in patients on 
OAT2,64,65,67,73–75,79,80 as well as in patients on antiplatelet therapy73,74,81. There is scant evidence 
that OAT intensity is associated with increased bleeding risk, but strong evidence that 











therapies with the potential for drug-drug interactions may substantially increase the risk of 
bleeding82–84, whereas the incidence of hospitalization for upper GIB was lower among DOAC-
treated patients receiving concomitant PPI therapy85. 
 
Clinical implications of oral factor Xa inhibitors’ underdosing on safety and efficacy 
outcomes 
Since in phase III RCTs patients received oFXaIs at appropriate doses, with a better benefit-
harm profile compared with subjects on warfarin, evidence about clinical implications of 
oFXaIs’ underdosing may be inferred only from observational real-life studies. In this context, 
except minor differences regarding renal function estimation formulas, consideration of 
potential drug-drug interactions and country-specific rivaroxaban dose differences, 
underdosing has been almost always defined as the prescription of RD oFXaIs not in keeping 
with the SmPC–specified dose reduction criteria. 
Table 1 summarizes the main efficacy and safety outcome results coming from real-world 
studies which evaluated the clinical implications of off-label RD use. In the ORBIT-AF II study, 
underdosing was associated with increased cardiovascular hospitalization, without reduced 
bleeding events and/or bleeding-related hospitalizations13. In the STANDARD study, including 
6306 NVAF subjects on apixaban, there was no evidence of increasing safety (MB or any 
bleeding event) with the use of off-label RD45. In a recent retrospective analysis including 1023 
patients on DOACs presenting in an emergency department, no significant difference was found 
with respect to bleeding according to DOAC dosing50. In a large sample of 16568 Korean 
outpatients, compared with warfarin, off-label RD rivaroxaban was associated with a lower risk 
of thromboembolic events and all-cause mortality, with a similar risk of MB, whereas off-label 
RD apixaban was associated with similar risks of thromboembolic events, all-cause mortality 











reduced effectiveness without a significant safety benefit30. In a retrospective analysis including 
6392 NVAF Asian outpatients, DOAC underdosing was associated with a 2.5-fold increased 
risk of thromboembolism compared with warfarin, with a comparable risk of MB47. 
Potential underdosing in 14865 NVAF patients who initiated DOAC therapy and did not meet 
renal criteria for RD use was found to be associated with a higher risk of stroke, particularly in 
apixaban-treated patients, without a significant difference in MB events; however, lack of data 
on BW strongly limited the correct assessment of off-label RD use in apixaban-treated 
patients22. Briasoulis et al reported that patients who received off-label RD rivaroxaban (12.9%) 
had an increased risk of MB, which was not significant after propensity score matching44. On 
the contrary, clinical outcomes were not worse for underdosed rather than correctly dosed 
subjects enrolled in the prospective multicenter SAKURA AF registry in Japan40. In a 
retrospective Spanish study of 2494 NVAF patients on DOAC, underdosing was associated 
with a non-significant higher death rate, without differences in MB and stroke49. After adjusting 
for patients’ characteristics by propensity scoring and inverse probability of treatment 
weighting, compared with patients who received the recommended dose, patients enrolled in 
the XAPASS study who received off-label RD rivaroxaban experienced comparable rates of 
MB and higher rates of stroke/SE and myocardial infarction35. Very similar findings were 
reported by Cheng et al in 2214 rivaroxaban-treated patients in Taiwan; compared with on-label 
dosing, off-label RD rivaroxaban was associated with an increased risk of ischemic stroke, and 
a negative net clinical benefit in different weighted models31. In a Korean study, on-label FD 
rivaroxaban showed better results for the composite clinical outcome (ischemic stroke, 
intracranial hemorrhage, hospitalization for GIB, all-cause death) compared with off-label 
RD38. Using data from the XANTUS study, Amarenco et al reported that use of off-label RD 
rivaroxaban was associated with a trend to less favorable outcomes (MB, stroke/SE, and death), 











analysis29. In a small retrospective study including 354 NVAF patients aged 80 years and over 
with non-severe frailty, 42 of 273 patients on DOAC (15.4%) were underdosed, without 
differences in the incidence of bleeding and thromboembolic events86. Paciaroni et al 
retrospectively investigated the risk factors for cerebrovascular ischemic events occurring 
during DOAC therapy for stroke prevention in AF in a sample of 713 cases (641 ischemic 
strokes and 72 TIAs) and 700 controls: on multivariate analysis, use of off-label RD was 
associated with a 3-fold increased risk of ischemic events87. In a prospective cohort study on 
1124 AF patients aged 85 years and older treated with VKAs (58.7%) or DOACs (41.3%), no 
thrombotic events occurred in the small group of underdosed DOAC patients88. Recent studies 
demonstrated that oFXaIs’ underdosing was associated with a higher stroke severity in patients 
admitted with ischemic stroke89, and  with a higher rate of major vascular occlusion in patients 
admitted with suspected ischemic stroke90. 
In conclusion, despite inherent limitations of observational studies, and with few 
exceptions40,86,88, there is consistent evidence that underdosing of oFXaIs is not associated with 




Despite the well demonstrated greater net clinical benefit of DOACs compared with warfarin 
in the general population and in older patients91,92, there is still a persistent underuse of OAT53,93 
and an increasing use of off-label RD of oFXaIs14. Our literature review, summarized in the 
Central Illustration, demonstrated that a substantial proportion of oFXaIs’ underdosing may be 
voluntary, suggesting a cautious approach to patients perceived to be at high risk of bleeding. 
However, available evidence suggests that patients’ characteristics (e.g., advanced age, 











NSAIDs) and underlying GI pathology, rather than with OAT intensity, are associated with 
the risk of bleeding events. Indeed, in oFXaIs’ RCTs, the rates of MB were consistently higher 
among patients treated with RD rather than in those treated with FD. Moreover, correct use of 
RD had reassuringly the same efficacy and safety as FD oFXaIs compared with warfarin66. 
Real-life studies do not provide evidence of a sizeable net clinical benefit by using off-label RD 
oFXaIs, but rather suggest an increased risk of adverse events, including hospitalizations for 
cardiovascular causes and stroke, without a significant reduction of bleeding events. 
All three oFXaIs show a first-order kinetic, which means that, at the dosage range tested, they 
show a linear correlation between their drug plasma concentrations (DPCs) and the 
pharmacodynamic (PD) inhibition of clotting factor X activated (FXa), without any tendency 
to reach a plateau. Such linearity is consistent and independent of age and sex94. On these bases, 
an inverse and a direct relationship of DPC with the probability of stroke/SE and MB, 
respectively, have been observed, although within-patient clinical variability complicates the 
interpretation of these results95. 
Indeed, it has been reported that treatment with off-label RD DOACs compared with on-label 
dose was associated with lower DPCs96, and that C-trough levels in the lowest level class were 
associated with a significantly increased incidence of thromboembolic events97. Use of a RD 
implicates halving the dose of apixaban (from 5 mg to 2.5 mg) and edoxaban (from 60 mg to 
30 mg) while reducing of only 25% the dose of rivaroxaban (from 20 mg to 15 mg) and of 33% 
(from 15 mg to 10 mg) in Japanese patients. Halving the dose of apixaban or edoxaban is 
associated to an approximate 50% proportional reduction of their maximum DPCs76,98. 
However, it must be taken into consideration that in the ENGAGE AF-TIMI 48 trial, the 
predefined halving of edoxaban dose was associated to only an approximate 25% reduction of 
DPC and anti-FXa activity76. Moreover, the investigation of the effects of low BW (≤50 kg) on 











a 24% higher rivaroxaban Cmax resulting in a 15% increase in prolongation of prothrombin 
time100. Thus, by considering the criteria for edoxaban dose reduction, such as BW ≤60 kg, 
estimated CrCl 30 to 50 ml/min, or concomitant use of verapamil or quinidine, DPCs of the 30 
mg dose were similar to those reached with 60 mg76. Very similar results were obtained for 
apixaban where a 25% reduction of DPC was observed in patients treated with 2.5 mg vs 5 mg 
when 2 of 3 dose reduction criteria of the ARISTOTLE study were met101. Finally, the DPCs 
of on-label rivaroxaban FD and RD were also superimposable102. These results suggest that 
DPCs, and thus activities, of all oFXaIs in patients prescribed on-label RDs are similar to those 
observed with on-label FD, thereby reinforcing prescription according to recommended dose.  
In our view, the main strength of the present study is the physician-centered approach we used 
to assess the reasons underlying the decision to underdose oFXaIs in selected patients, the 
inconsistent and frail pharmacologic and clinical background supporting this strategy, and the 
clinical safety and efficacy implications of underdosing in real-life studies. The major limitation 
of the present study is that the evidence about the clinical implications of underdosing derives 
from observational studies, which have inherent weaknesses. Most of these studies are registry-
based, mainly retrospective, with potential for residual confounding from unmeasured 
variables, such as over-the-counter use of aspirin, polypharmacy, drug-drug interactions, body 
size and general health status. Moreover, these studies are heterogeneous, differing for clinical 
setting, country and ethnic groups, definition of potential underdosing and clinical outcomes 
considered. Eventually, most patients were treated with apixaban and rivaroxaban, with a small 
proportion of patients on edoxaban. Notwithstanding these limitations, the available evidence 
is quite consistent, and does not suggest a potential benefit from oFXaIs’ underdosing. At the 
same time, even if current evidence is not sufficient to allow any speculation about possible 
safety or efficacy differences among different oFXaIs used at inappropriate RDs, there are quite 











detrimental, in apixaban-treated patients. Being hard to imagine the ethical and practical 
feasibility of a RCT assessing the potential clinical benefit of off-label oFXaI RDs in selected 
patients, only prospective, dedicated, observational real-life studies involving subjects at high 
risk of underdosing (older polypathologic NVAF patients) might further shed some light on this 
topic. In these patients, OAT prescription is often a troublesome decision, involving a global 
evaluation of health, residual life-expectancy, functional and cognitive status, rather than a 
simple addition of variables within cardio-embolic and bleeding risk scales53,54. In keeping with 
current recommendations not to undertreat older frail patients55,  our review demonstrates that 
oFXaIs’ underdosing may be associated with a reduced efficacy without greater safety, thereby 
implying a poor benefit and possible harm from this strategy. At the moment, less is not more, 
in this case. 
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Table 1. Clinical outcomes associated with off-label reduced dose oral factor Xa inhibitors in relevant clinical studies 
 
Study Setting, population and definition of 
off-label RD oFXaIs’ use  
Incidence rate/proportion (absolute number) of 
selected clinical outcomes (unadjusted) 
Clinical outcomes associated with off-
label RD oFXaIs use 
Steinberg BA 
et al, 201613 
U.S.A.: 5738 NVAF outpatients on 
DOAC (median age 71 ys, 41.8% 
female), 9.4% underdosed (RD use not 
consistent with FDA-SmPC)  
3078 RI, 2235 AP, 425 DA 
Median follow-up: 0.99 ys 
Ischemic stroke/SE/TIA: 1.32% (n=70) on-label 
dose DOACs, 1.95% (n=11) off-label RD DOACs 
MB: 3.59% (n=187) on-label dose DOACs, 4.12% 
(n=23) off-label RD DOACs 
MI: 0.77% (n=41) on-label dose DOACs, 1.06% 
(n=6) off-label RD DOACs 
All hospitalization: 42.77% (n=1727) on-label dose 
DOACs, 48.56% (n=212) off-label RD DOACs 
CV hospitalization: 24.16% (n=1093) on-label dose 
DOACs, 26.11% (n=129) off-label RD DOACs 
Bleeding hospitalization: 2.91% (n=152) on-label 
dose DOACs, 4.12% (n=23) off-label RD DOACs 
Increased CV hospitalization (aHR 1.26; 
95% CI 1.07-1.50). Non-significant 













All-cause mortality: 2.95% (n=158) on-label dose 
DOACs, 6.30% (n=36) off-label RD DOACs 
Yao X et al, 
201722 
U.S.A.: 13392 NVAF patients on 
DOAC with no renal indication for RD 
(median age 70 ys, 41.8% female). 
3340 AP, 5399 RI, 4653 DA 
Off-label RD (RD use in the absence of 
a renal indication): 13.3% (AP 16.5%, 
RI 15.1%, DA 8.9%) 
Median follow-up: 4.0 mo 
Ischemic stroke/SE: 1.43%/y (n=14) on-label FD 
DOACs, 1.70%/y (n=16) off-label RD DOACs 
MB: 5.03%/y (n=49) on-label FD DOACs / 5.43%/y 
(n=51) off-label RD DOACs  
Off-label RD vs on-label FD AP associated 
with higher stroke risk (HR 4.87; 95% CI 
1.30-18.26), but similar MB risk (HR 1.29; 
95% CI 0.48-3.42). No differences in 
stroke or MB risk between off-label RD 
and on-label FD RI. 
Sato T et al, 
201825 
Japan: 2272 NVAF patients on DOAC 
(mean age 72 ys, 37% female), 498 RI†, 
1014 AP, 267 ED, 493 DA 
Off-label RD (RD use not consistent 
with Japan SmPC†): 21.6% (490); RI 
23.9%, AP 22.5%, ED 12.4%, A 20.7% 
Follow-up: up to 2 ys 
Stroke/SE: 2.2%/y on-label dose DOACs, 2.4%/y 
off-label RD DOACs 
MB: 2.0%/y on-label dose DOACs, 2.4%/y off-label 
RD DOACs 
GIB: 1.1%/y on-label dose DOACs, 1.0%/y off-label 
RD DOACs 
No significant differences in stroke/SE and 
MB between on-label dose DOACs and 











ICH: 0.3%/y on-label dose DOACs, 1.2%/y off-label 
RD DOACs 
All-cause mortality: 2.3%/y on-label dose DOACs, 
2.6%/y off-label RD DOACs 
Steinberg BA 
et al, 201826  
U.S.A.: 7925 NVAF outpatients on 
DOAC (mean age 71.0 ys, 41.3% 
female) 3833 RI, 3528 AP, 70 ED, 494 
DA 
Off-label RD (RD use not consistent 
with FDA SmPC): 9.3% (734) 
Median follow-up: 1.0 ys 
Stroke/SE/TIA: 1.35%/y (n=91) on-label FD RI or 
AP, 2.11%/y (n=16) off-label RD RI or AP 
MB: 2.84%/y (n=189) on-label FD RI or AP, 
4.28%/y (n=32) off-label RD RI or AP 
MI: 0.60%/y (n=41) on-label FD RI or AP, 0.78%/y 
(n=6) off-label RD RI or AP 
Bleeding hospitalization: 2.38%/y (n=159) on-label 
FD RI or AP, 3.60%/y (n=27) off-label RD RI or AP 
All-cause mortality: 2.60%/y (n=177) on-label FD 
RI or AP, 6.77%/y (n=52) off-label RD RI or AP 
Off-label RD vs on-label FD in patients 
receiving either RI or AP showed higher 
unadjusted rates of stroke/SE/TIA (HR 
1.56, 95% CI 0.92‐ 2.67), MB (HR 1.49, 
95% CI 1.02‐ 2.18), and overall mortality 
(HR 2.61, 95% CI 1.86‐ 3.67), with 
borderline non-significant values after 
multivariate adjustment, 
Amarenco P 
et al, 201929 
Europe, Canada, Israel: subanalysis on 
4464 NVAF patients on RI. 
MB/stroke/SE/all-cause mortality: 4.8%/y (n=157, 
4.4%) on-label dose RI, 7.6%/y (n=39, 6.7%) off-
label RD RI 
Off-label RD RI vs on-label dose RI was 
associated with a higher risk of the 











Off-label RD RI (RD use not consistent 
with SmPC) 13.1% (583) 
Follow-up: 1 ys 
Stroke/SE/MI: 1.9%/y (n=62, 1.7%) on-label dose 
RI, 2.7%/y (n=14, 2.4%) off-label RD RI 
MB: 2.6%/y (n=86, 2.4%) on-label dose RI, 3.9%/y 
(n=20, 3.4%) off-label RD RI 
ICH: 0.5%/y (n=15, 0.4%) on-label dose RI, 1.0%/y 
(n=5, 0.9%) off-label RD RI 
Fatal bleeding: 0.2%/y (n=7, 0.2%) on-label dose RI, 
0.4%/y (n=2, 0.3%) off-label RD RI 
All-cause mortality: 1.9%/y (n=62, 1.7%) in-label 
dose RI, 3.1%/y (n=16, 2.7%) off-label RD RI 
death (HR 1.57, 95% CI 1.10-2.22), but not 
after multivariate adjustment 
Arbel R et al, 
201930 
Israel: 8425 NVAF outpatients on on-
label FD or off-label RD DOAC (56.4% 
>75 ys, 51.9% female) 
Off-label RD (RD use non consistent 
with drug label): 3285 (39%)  
Overall mortality/stroke/MI:8.7% (n=447) on-label 
dose DOACs, 22.8% (n=749) off-label RD DOACs 
Stroke:1.6% (n=84) on-label dose DOACs, 2.6% 
(n=86) off-label RD DOACs 
MI:0.93% (n=48) on-label dose DOACs, 1.3% 
(n=44) off-label RD DOACs 
Off-label RD use compared with on label 
FD was associated with a higher rate of the 
composite of overall mortality/stroke/MI 
(aHR 1.57, 95% CI 1.34-1.83) and a higher 
rate of bleeding events requiring 












Bleeding hospitalization: 1.6% (n=80) on-label dose 
DOACs, 3.1% (n=101) off-label RD DOACs 
All-cause mortality: 6.9% (n=354) on-label dose 
DOACs, 20.9% (n=686) off-label RD DOACs 
Cheng W-H 
et al, 201931 
Taiwan: 2214 NVAF patients on RI‡ 
(mean age 75.7 ys, 36% female) 
Off-label RD (RD use non consistent 
with J-ROCKET study‡): 26.4% (584)  
Mean follow-up: 2.10 ys 
Ischemic stroke: 0.86%/y (n=32) on-label dose RI, 
2.82%/y (n=29) off-label RD RI 
ICH: 1.14%/y (n=42) on-label dose RI, 1.16%/y 
(n=12) off-label RD RI 
Compared with the on-label dose group, 
off-label RD RI was associated with an 
increased risk of ischemic stroke (aHR 
2.75, 95% CI 1.62-4.69), and with a 
negative net clinical benefit (aHR 1.54, 
95% CI 1.02-2.31) in different weighted 
models, no significant differences in ICH 
Ikeda T et al, 
201935 
Japan: 6521 NVAF patients on RI† and 
CrCl ≥50 ml/min.  
Off-label RD (RD use not consistent 
with Japan SmPC†): 35.8% 
Mean follow-up 305 days 
Stroke/SE/MI: 1.48%/y on-label FD RI, 2.15%/y 
off-label RD RI 
Any bleeding: 8.05%/y on-label FD RI, 5.29%/y off-
label RD RI 
MB: 1.63%/y on-label FD RI, 1.34%/y off-label RD 
RI 
Off-label RD RI resulted in a lower 
incidence of the primary safety outcome 
(any bleeding; HR 0.66, 95% CI 0.57–
0.76), without a significant difference in 











ICH: 0.64%/y on-label FD RI, 0.75%/y off-label RD 
RI 
Fatal bleeding: 0.14%/y on-label FD RI, 0.06%/y 
off-label RD RI 
Ischemic stroke: 1.09%/y on-label FD RI, 1.26%/y 
off-label RD RI 
MI: 0.05%/y on-label FD RI, 0.09 per 100 person/ys 
off-label RD RI 
effectiveness outcome (stroke/SE/MI; HR 
1.45, 95% CI 1.10–1.91)  
Lee S-R, 
Stroke 201938 
Korea: 33980 NVAF patients with CrCl 
>50 ml/min, no previous ischemic 
stroke/ICH/GIB (mean age 66.9 ys, 
37.8% female), 20431 on VKA, 13549 
on RI 
Off-label RD RI (RD RI use in the 
absence of a renal indication): 42.8% 
Median follow-up 1.4 ys 
Ischemic stroke/ICH/hospitalization due to GIB or 
ICH/all-cause mortality*: 7.07%/y (n=349/5196) 
on-label FD RI, 8.47%/y (n=361/5196) off-label RD 
RI 
Ischemic stroke*: 2.16%/y (n=108/5196) on-label 
FD RI, 2.55%/y (n=110/5196) off-label RD RI 
MB (ICH/GIB) hospitalization*: 2.28%/y 
(n=114/5196) on-label FD RI, 2.71%/y 
(n=117/5196) off-label RD RI 
On-label FD RI vs off-label RD RI showed 
a significantly lower incidence of the 
composite of ischemic 
stroke/ICH/hospitalization due to GIB or 
ICH/all-cause death (HR 0.85, 95% CI 
0.74-0.99), but no significant difference 











ICH*: 0.89%/y (n=45/5196) on-label FD RI, 
0.83%/y (n=36/5196) off-label RD RI 
GIB hospitalization*: 1.41%/y (n=71/5196) on-label 
FD RI, 1.89%/y (n=82/5196) off-label RD RI 
All-cause mortality*: 3.60%/y (n=182/5196) on-
label FD RI, 4.32%/y (n=189/5196) off-label RD RI 
Murata N et 
al, 201940 
Japan: 1676 NVAF outpatients on 
DOAC (mean age 71.7 ys, 28.5% 
females), RI† 45.5%, AP 25.6%, ED 
1.9%, DA 27.1% 
Off-label RD (RD use not consistent 
with Japan SmPC†): 22.2%. 
 
Median follow-up: 39.3 mo  
Ischemic stroke/TIA/SE: 1.17%/y (n=25, 3.3%) on-
label FD DOACs, 2.07%/y (n=27, 5.6%) on-label 
RD DOACs, 1.02%/y (n=11, 2.9%) off-label RD 
DOACs 
MB: 1.21%/y (n=26, 3.5%) on-label FD DOACs, 
1.45%/y (n=19, 4.0%) on-label RD DOACs, 
0.64%/y (n=7, 1.9%) off-label RD DOACs 
ICH: 0.46%/y (n=10, 1.3%) on-label FD DOACs, 
0.53%/y (n=7, 1.5%) on-label RD DOACs, 0.37%/y 
(n=4, 1.1%) off-label RD DOACs 
Ischemic stroke/TIA/SE, mortality and 
MB did not significantly differ between the 
on-label FD, and off-label RD groups, 











All-cause mortality: 0.64%/y (n=14, 1.9%) on-label 
FD DOACs, 4.07%/y (n=54, 11.3%) on-label RD 




et al, 201949 
Spain: 2494 NVAF patients on DOAC 
(mean age 76 ys, 52.9% female), RI 
41.1%, AP 38.5%, ED 2.8%, DA 17.6% 
Off-label DOAC dose in 517 patients 
(23.5%), FXaI mainly underdosed 
(dose not consistent with SmPC); RI 
26.1%, AP 21.2%, ED 23.9%, DA 
22.8% 
Mean follow-up 20.2 mo 
Ischemic stroke: 1.8%/y (n= 52/1682, 3.1%) on-
label dose DOACs, 2.0%/y (n= 15/441, 3.4%) off-
label RD DOACs. 
MB: 3.0%/y (n= 87/1682, 5.2%) on-label dose 
DOACs, 3.3%/y (n= 25/441, 5.7%) off-label RD 
DOACs. 
ICH: 0.3%/y (n= 10/1682, 0.6%) on-label dose 
DOACs, 0.4%/y (n= 3/441, 0.7%) off-label RD 
DOACs. 
All-cause mortality: 5.1%/y (n= 142/1682, 8.4%) 
on-label dose DOACs, 9.3%/y (n= 69/441, 15.6%) 
off-label RD DOACs. 
Off-label RD patients showed a non-
significant higher overall mortality, and no 












et al, 202044 
U.S.A.: 27747 Medicare beneficiaries 
with AF, 19712 on RI, 8035 on DA 
Off-label RD RI (RD use without eGFR 
<50 ml/min or drug-drug interactions): 
12.9% (2551) 
Mean follow up: 13 mo 
Ischemic stroke: 0.026/ys (n=256) on-label FD RI, 
0.057/ys (n=176) on-label RD RI, 0.040/ys (n=89) 
off-label RD RI 
MB: 0.043/ys (n=426) on-label FD RI, 0.099/ys 
(n=307) on-label RD RI, 0.067/ys (n=147) off-label 
RD RI 
ICH: 0.004/ys (n=38) on-label FD RI, 0.008/ys 
(n=25) on-label RD RI, 0.006/ys (n=13) off-label 
RD RI 
GIB: 0.034/ys (n=341) on-label FD RI, 0.078/ys 
(n=243) on-label RD RI, 0.050/ys (n=111) off-label 
RD RI 
Compared with the on-label FD RI dose 
group, the off-label RD RI group showed 
similar rates of stroke, ICH and GIB, and a 
higher rate of MB (HR 1.35, 95% CI 1.12-
1.6), that was not confirmed after 
controlling for several patients’ 
characteristics in propensity-matched 
samples 
Cho MS et al, 
202020 
Korea: 16568 NVAF outpatients on 
OAT and no indication to RD use 
(56.1% female) 
Off-label RD (RD use inconsistent with 
SmPC): 51.6% (8549/16568 patients on 
Ischemic stroke/SE: 2.30%/y (n=197, 2.5%) on-label 
FD DOACs, 2.38%/y (n=226, 2.6%) off-label RD 
DOACs; 2.47%/y (n=128, 2.7%) on-label FD RI, 
2.02%/y (n=106, 2.2%) off-label RD RI; 2.04%/y 
Off-label RD RI vs on-label FD RI: no 
significant differences in ischemic 
stroke/SE, overall mortality and MB. Off-
label RD AP vs in-label AP: non-











DOAC); RI 50.6% (mean age 71.4 ys), 
AP 53.0% (mean age 73.0 ys) 
Median follow up: 15 mo 
(n=69, 2.1%) on-label FD AP, 2.88%/y (n=120, 
3.3%) off-label RD AP 
MB: 1.51%/y (n=151, 1.9%) on-label FD DOACs, 
1.99%/y (n=187, 2.2%) off-label RD DOACs; 
1.69%/y (n=99, 2.1%) on-label FD RI, 2.20%/y 
(n=119, 2.4%) off-label RD RI; 1.24%/y (n=52, 
1.6%) on-label FD AP, 1.72%/y (n=68, 1.9%) off-
label RD AP 
All-cause mortality: 1.59%/y (n=135, 1.7%) on-label 
FD DOACs, 2.38%/y (n=205, 2.4%) off-label RD 
DOACs; 1.70%/y (n=86, 1.8%) on-label FD RI, 
1.89%/y (n=95, 2.0%) off-label RD RI; 1.42%/y 
(n=49, 1.5%) on-label FD AP, 3.04%/y (n=110, 
3.0%) off-label RD DOACs  
(aHR 1.27, 95% CI 1.00-1.63), higher 
overall mortality (aHR 1.49, 95% CI 1.12-
1.97), no significant differences in MB. 
Eschler CM 
et al, 202050 
Switzerland: 19662 consecutive 
emergency department admissions, 
1721 (9%) on OAT (mean age 77 ys, 
Bleeding presentation in the emergency department: 
9.6% of patients on OAT (n=166) 
Only use of ASA (OR 1.7, 95% CI 1.0-2.8) 
was associated with bleeding presentation 











47% female, 63.2% for NVAF): VKAs 
(40.7%), RI (35.8%), AP (18.7%), ED 
(4.4%), DA (0.5%) 
175 (17.1%) of DOACs off-label RD 
(RD use not consistent with SmPC, 
according to diagnosis); 345 (20%) of 
the overall sample was underdosed 
(including subtherapeutic AVKs) 
166 cases (9.6%) presented to the ED 
with bleeding 
likelihood of severe bleeding (p = 0.042). 
No significant association among 
anticoagulant molecules and bleeding or 
in-hospital mortality. 
Inoue H et al, 
202045 
Japan: 6306 NVAF on AP (72.8% ≥70 
ys, 41.1% female), 15% underdosed 
(RD use not consistent with Japan 
SmPC) 
Mean follow-up: 17.4 mo.  
Ischemic stroke/SE/TIA: 0.70%/y (n=33) on-label 
FD AP, 1.69%/y (n=37) on-label RD AP, 0.95%/y 
(n=13) off-label RD AP 
MB: 2.00%/y (n=94) on-label FD AP, 3.30%/y 
(n=72) on-label RD AP, 2.50%/y (n=34) off-label 
RD AP 












ICH: 0.57%/y (n=27) on-label FD AP, 1.14%/y 
(n=25) on-label RD AP, 0.88%/y (n=12) off-label 
RD AP 
Major GIB: 0.89%/y (n=42) on-label FD AP, 
1.60%/y (n=35) on-label RD AP, 0.80%/y (n=11) 
off-label RD AP 
Any bleeding: 4.80%/y (n=221) on-label FD AP, 
7.01%/y (n=150) on-label RD AP, 5.53%/y (n=74) 
off-label RD AP 
Lee K-N et al, 
202047 
Korea: 3733 NVAF outpatients on 
DOAC (mean age 68.0 ys, 37.6% 
female), 2659 on warfarin 
Off-label RD DOAC (RD use not 
consistent with Korea SmPC) 20.3% 
Mean follow-up: 6.3 months (DOAC 
group) vs 9.9 months (warfarin group) 
Ischemic stroke/SE/MI/intracavitary thrombus: 
1.35%/y warfarin, 1.05%/y on-label FD DOACs, 
1.94%/y on-label RD DOACs, 2.73%/y off-label RD 
DOACs 
MB: 2.14%/y warfarin, 0.89%/y on-label FD 
DOACs, 1.23%/y on-label RD DOACs, 1.46%/y 
off-label RD DOACs 
Compared with warfarin, off-label RD 
group had an increased risk of ischemic 
stroke/SE/MI/intracavitary thrombus (aHR 
 2.51, 95% CI 1.28–4.93) in several 
adjusted models, and a higher risk of MB 
in the unadjusted model (HR 6.16; 95% 













† = in Japan, approved doses of RI are 15 mg once daily FD and 10 mg once daily for RD, with the same criteria for RD use as European-approved 
doses; ‡including patients both in Japan-approved (i.e. 15 mg/10 mg once daily) and in European-approved doses (i.e. 20mg/15 mg once daily), 
considering only 10 mg once daily as underdosed in absence of criteria for RD use; *in propensity score-matched cohorts 
 
Abbreviations: AF = atrial fibrillation; aHR = adjusted hazard ratio; AP = apixaban; ASA = acetylsalycilic acid, CI = confidence interval, CRNMB 
= clinically relevant non major bleeding, CV = cardiovascular, DA = dabigatran; DOAC = direct oral anticoagulant, ED = edoxaban, eGFR = 
estimated glomerular filtration rate, FD = full dose, FDA = Food and Drug Administration, FXaI = factor Xa inhibitor, GIB = gastro-intestinal 
bleeding, HR = hazard ratio, ICH = intracranial hemorrhage, MB = major bleeding, MI = myocardial infarction, mo = months, NVAF = nonvalvular 
atrial fibrillation, OAT = oral anticoagulant therapy, OR = odds ratio, RD = reduced dose, RI = rivaroxaban, SE = systemic embolism, SmPC = 
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